When developing antimalarial drugs, scientists must be prepared to be flexible, as parasites develop resistance to already developed drugs. All early drugs against malaria are based on blocking the myosin motor components MyoA and MTIP (Kortagere et al., 2010). These components allow malaria to grow, which gives rise to patients’ need for inhibitors that block all invasive stages. The fundamental task of antimalarial drugs is to stop the MyoA and MTIP complex. The experience of creating drug compounds teaches that it is necessary to develop not one drug but a whole range of medicines to produce a choice for both scientists and patients.
Creating a range of medicines, rather than focusing on just one, will help create a competitive environment in the pharmaceutical industry. This environment will be beneficial to patients and physicians, as it will allow them to be the first to evaluate their financial strengths and choose drugs according to them (Kayiba et al., 2021). For the latter, it will be a chance for choice in terms of offerings and flexibility in treatment (Kigozi et al., 2020). Different types of treatment may be suitable for children, people with disabilities, with chronic diseases.
The economic aspect is crucial in the development of antimalarial drugs. Resistance forces companies to be constantly in good shape when developing new and new drugs (Conteh et al., 2021). However, the price of such drugs is also rising, negatively affecting aid to third-world countries and African and Asian regions (Jongdeepaisal et al., 2021). Previously cheap pills are now simply inadequate for human treatment due to the resistance of the MyoA and MTIP complex. Now it looks like the medical and global community has forgotten about the malaria problem. However, it is not the case, and drug development should continue, perhaps in areas close to malaria outbreaks. It raises the question of ease of production and the possibility of training qualified specialists, doctors, biologists and chemists.
Thus, further development of blocker drugs is needed to treat patients. These patients may be of different incomes, origins, ages and health indicators. Malaria is resistant to drugs; therefore, making cheap drugs against this disease has failed. Third world countries were left alone with their problems due to the need to create new medicines repeatedly. These developments in the modern pharmaceutical market increase diversity, opening treatment options for a wide variety of populations.
References
Conteh, L., Shuford, K., Agboraw, E., Kont, M., Kolaczinski, J., & Patouillard, E. (2021). Costs and cost-effectiveness of malaria control interventions: A systematic literature review. Value in Health, 24(8), 1213–1222. Web.
Jongdeepaisal, M., Ean, M., Heng, C., Buntau, T., Tripura, R., Callery, J. J., Peto, T. J., Conradis-Jansen, F., von Seidlein, L., Khonputsa, P., Pongsoipetch, K., Soviet, U., Sovannaroth, S., Pell, C., & Maude, R. J. (2021). Acceptability and feasibility of malaria prophylaxis for forest goers: Findings from a qualitative study in Cambodia. Malaria Journal, 20(1), 25-47. Web.
Kayiba, N. K., Yobi, D. M., Devleesschauwer, B., Mvumbi, D. M., Kabututu, P. Z., Likwela, J. L., Kalindula, L. A., DeMol, P., Hayette, M. P., Mvumbi, G. L., Lusamba, P. D., Beutels, P., Rosas-Aguirre, A., & Speybroeck, N. (2021). Care-seeking behaviour and socio-economic burden associated with uncomplicated malaria in the Democratic Republic of Congo. Malaria Journal, 20(1), 90-113. Web.
Kigozi, S. P., Kigozi, R. N., Epstein, A., Mpimbaza, A., Sserwanga, A., Yeka, A., Nankabirwa, J. I., Halliday, K., Pullan, R. L., Rutazaana, D., Sebuguzi, C. M., Opigo, J., Kamya, M. R., Staedke, S. G., Dorsey, G., Greenhouse, B., & Rodriguez-Barraquer, I. (2020). Rapid shifts in the age-specific burden of malaria following successful control interventions in four regions of Uganda. Malaria Journal, 19(1), 299-325. Web.
Kortagere, S., Welsh, W. J., Morrisey, J. M., Daly, T., Ejigiri, I., Sinnis, P., Vaidya, A. B., & Bergman, L. W. (2010). Structure-based design of novel small-molecule inhibitors of Plasmodium falciparum. Journal of Chemical Information and Modeling, 50(5), 840–849. Web.